Understanding the potential role of statins in pneumonia and sepsis

Critical Care Medicine

Volumn 39, Issue 8, 2011, Pages 1871-1878

  Yende, Sachin ^a   Milbrandt, Eric B ^a   Kellum, John A ^a   Kong, Lan ^b   Delude, Russell L ^a   Weissfeld, Lisa A ^b   Angus, Derek C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

coagulation; community acquired pneumonia; outcomes; sepsis; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTITHROMBIN; ATORVASTATIN; BLOOD CLOTTING FACTOR 9; CELL SURFACE PROTEIN; CORTICOSTEROID; D DIMER; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 6; MEVINOLIN; PLASMINOGEN ACTIVATOR INHIBITOR; PNEUMOCOCCUS VACCINE; PRAVASTATIN; SIMVASTATIN; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR;

AGED; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; FUNCTIONAL STATUS; HEALTH INSURANCE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFECTION RISK; INFLUENZA VACCINATION; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; MULTICENTER STUDY; NURSING HOME PATIENT; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SEPSIS; SMOKING; UNITED STATES;

EID: 79961024148     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31821b8290     Document Type: Article

References (47)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389
2. Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307
3. Undas A, Brummel KE, Musial J, et al: Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103: 2248-2253 (Pubitemid 32433713)
4. Almog Y: Statins, inflammation, and sepsis: Hypothesis. Chest 2003; 124:740-743 (Pubitemid 37000158)
5. Kruger PS, Freir NM, Venkatesh B, et al: A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med 2009; 35: 717-721
6. Kopterides P, Falagas ME: Statins for sepsis: A critical and updated review. Clin Microbiol Infect 2009; 15:325-334
7. Saint Martin L, Tandé D, Goetghebeur D, et al: Statin use does not affect the outcome of acute infection: A prospective cohort study. La Presse Médicale 2010; 39:e52-e57
8. Janda S, Young A, Fitzgerald JM, et al: The effect of statins on mortality from severe infections and sepsis: A systematic review and meta-analysis. J Crit Care 2010; 25: 656-722
9. Bjorkhem-Bergman L, Bergman P, Andersson J, et al: Statin treatment and mortality in bacterial infections-A systematic review and meta-analysis. PLoS One 2010; 19: e10702
10. Chopra V, Flanders SA: Does statin use improve pneumonia outcomes? Chest 2009; 136:1381-1388
11. Viasus D, Garcia-Vidal C, Gudiol F, et al: Statins for community-acquired pneumonia: Current state of the science. Eur J Clin Microbiol Infect Dis 2010; 29:143-152
12. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333 (Pubitemid 34761611)
13. Majumdar SR, McAlister FA, Eurich DT, et al: Statins and outcomes in patients admitted to hospital with community acquired pneumonia: Population based prospective cohort study. BMJ 2006; 333:999
14. Statins in Sepsis Study (STATInS). Available at: http://www.anzctr.org. au/ACTRN1260700 0028404.aspx. Accessed March 10, 2008
15. The Influence of Statins on Blood Vessel Function in Severe Sepsis. Available at: http://www.anzctr.org.au/ACTRN12607000393459. aspx. Accessed March 10, 2008
16. Statins for the Early Treatment of Sepsis (SETS). Available at: http://clinicaltrials.gov/show/NCT00528580. Accessed March 10, 2008
17. Simvastatin and Severe Sepsis: A randomised controlled Trial (SimSepT). Available at: http://www.controlled-trials.com/ISRCTN92093279/. Accessed March 10, 2008
18. Hydroxymethylglutaryl-CoA reductase inhibition in Acute lung injury to Reduce Pulmonary oedema and inflammation (HARP). Available at: http://www.controlled-trials com/ISRCTN70127774/. Accessed March 10, 2008
19. Randomised double-blind placebo-controlled trial of 40 mg/day of Atorvastatin on reduction in severity of SEPSIS in ward patients (ASEPSIS). Available at: http://www.controlledtrials. com/ISRCTN64637517/. Accessed March 10, 2008
20. Effect of Rosuvastatin in Abdominal Sepsis. Available at: http://clinicaltrials.gov/ct2/show/NCT00357123. Accessed March 8, 2008
21. Statin for Immunomudulation in Sepsis. Available at: http:// clinicaltrials.gov/ct2/show/NCT00452608. Accessed March 8, 2008
22. Simvastatin in Patients With Septic Shock. Available at: http://clinicaltrials.gov/ct2/show/NCT00450840. Accessed March 10, 2008
23. Statin Therapy in the Treatment of Sepsis. Available at: http://clinicaltrials.gov/ct2/show/NCT00676897. Accessed May 20, 2009
24. Pravastatin and Ventilator Associated Pneumonia (EPRAVAP). Available at: http://clinicaltrials. gov/ct2/show/NCT00702130. Accessed May 20, 2009
25. Huang DT, Weissfeld LA, Kellum JA, et al: Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008; 52:48-58
26. Kellum JA, Kong L, Fink MP, et al: Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167: 1655-1663 (Pubitemid 47280347)
27. Reade MC, Weissfeld L, Angus DC, et al: The prevalence of anemia and its association with 90-day mortality in hospitalized communityacquired pneumonia. BMC Pulm Med 2010; 10:15
28. Mayr FB, Yende S, D'Angelo G, et al: Do hospitals provide lower quality of care to black patients for pneumonia? Crit Care Med 2010; 38:759-765
29. Milbrandt EB, Reade MC, Lee M, et al: Prevalence and significance of coagulation abnormalities in community-acquired pneumonia. Mol Med 2009; 15:438-445
30. Fine MJ, Auble TE, Yealy DM, et al: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250 (Pubitemid 27044625)
31. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40:373-383 (Pubitemid 17055592)
32. Knaus WA, Wagner DP, Draper EA, et al: The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100: 1619-1636
33. Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-1256
34. Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-710 (Pubitemid 26254283)
35. Vincent JL, Sakr Y, Sprung CL, et al: Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006; 34: 344-353 (Pubitemid 43145611)
36. Niederman MS, Mandell LA, Anzueto A, et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-1754 (Pubitemid 32578779)
37. Cohen J, Guyatt G, Bernard GR, et al: New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med 2001; 29:880-886 (Pubitemid 32299732)
38. Angus DC, Carlet J; on behalf of the 2002 Brussels Roundtable Participants: Surviving intensive care: A report from the 2002 Brussels Roundtable. Intensive Care Med 2003; 29:368-377 (Pubitemid 36379436)
39. Yende S, van der PT, Lee M, et al: The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: Analysis of two multicentre cohort studies. Thorax 2010; 65:870-877
40. Epstein MP, Lin X, Boehnke M. A Tobit variance-component method for linkage analysis of censored trait data. Am J Hum Genet 2003; 72:611-620 (Pubitemid 36255960)
41. Brown H, Prescott R: Applied Mixed Models in Medicine: Statistics in Practice. New York, John Wiley & Sons, 2000, pp 1-428
42. Laird NM, Ware JH: Random-effects models for longitudinal data. Biometrics 1982; 38: 963-974
43. Liang KY, Zeger SL: Longitudinal data anal-ysis using generalized linear models. Biometrika 1986; 73:13-22
44. Braitman LE, Rosenbaum PR: Rare outcomes, common treatments: Analytic strategies using propensity scores. Ann Intern Med 2002; 137:693-695 (Pubitemid 35176104)
45. Brookhart MA, Patrick AR, Dormuth C, et al: Adherence to lipid-lowering therapy and the use of preventive health services: An investigation of the healthy user effect. Am J Epidemiol 2007; 166:348-354 (Pubitemid 47216808)
46. Dormuth CR, Patrick AR, Shrank WH, et al: Statin adherence and risk of accidents: A cautionary tale. Circulation 2009; 119:2051-2057
47. Dublin S, Jackson ML, Nelson JC, et al: Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ 2009; 338:b2137